{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:15:29Z","timestamp":1790806529893,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004032","name":"Jilin University, China","doi-asserted-by":"publisher","award":["451170102027"],"award-info":[{"award-number":["451170102027"]}],"id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004032","name":"Jilin University, China","doi-asserted-by":"publisher","award":["451170102020"],"award-info":[{"award-number":["451170102020"]}],"id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004032","name":"Jilin University, China","doi-asserted-by":"publisher","award":["1G317L321461"],"award-info":[{"award-number":["1G317L321461"]}],"id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.biomaterials.2018.03.013","type":"journal-article","created":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T06:30:35Z","timestamp":1521009035000},"page":"80-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"special_numbering":"C","title":["Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy"],"prefix":"10.1016","volume":"167","author":[{"given":"Rong","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Meguellati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.biomaterials.2018.03.013_bib1","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1056\/NEJMe1012071","article-title":"Genetics, epigenetics, and leukemia","volume":"363","author":"Shannon","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.biomaterials.2018.03.013_bib2","first-page":"S4","article-title":"DNA methylation and gene silencing in cancer, Nature clinical practice","volume":"2","author":"Baylin","year":"2005","journal-title":"Oncology"},{"issue":"11","key":"10.1016\/j.biomaterials.2018.03.013_bib3","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biomaterials.2018.03.013_bib4","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/leu.2016.349","article-title":"Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells","volume":"31","author":"Yan","year":"2017","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.biomaterials.2018.03.013_bib5","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1158\/1078-0432.CCR-17-0235","article-title":"Inactivation of receptor tyrosine kinases reverts aberrant DNA methylation in acute myeloid leukemia","volume":"23","author":"Shen","year":"2017","journal-title":"Clin. Canc. Res. Off. J. Am. Ass. Canc. Res."},{"issue":"21","key":"10.1016\/j.biomaterials.2018.03.013_bib6","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"20","key":"10.1016\/j.biomaterials.2018.03.013_bib7","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/jnci\/djj447","article-title":"Epigenetic cancer therapy makes headway","volume":"98","author":"Mack","year":"2006","journal-title":"J.\u00a0Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.biomaterials.2018.03.013_bib8","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biomaterials.2018.03.013_bib9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10637-013-0045-6","article-title":"A\u00a0phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma","volume":"32","author":"Rosenberg","year":"2014","journal-title":"Invest. N. Drugs"},{"issue":"12","key":"10.1016\/j.biomaterials.2018.03.013_bib10","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1016\/j.biomaterials.2014.01.019","article-title":"Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas","volume":"35","author":"Li","year":"2014","journal-title":"Biomaterials"},{"issue":"31","key":"10.1016\/j.biomaterials.2018.03.013_bib11","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1016\/j.biomaterials.2011.07.004","article-title":"Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery","volume":"32","author":"Guo","year":"2011","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.biomaterials.2018.03.013_bib12","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1039\/C4CS00357H","article-title":"Nucleic acid aptamers in cancer research, diagnosis and therapy","volume":"44","author":"Ma","year":"2015","journal-title":"Chem. Soc. Rev."},{"issue":"14","key":"10.1016\/j.biomaterials.2018.03.013_bib13","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.18632\/oncotarget.2131","article-title":"A\u00a0nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis","volume":"5","author":"Shen","year":"2014","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.biomaterials.2018.03.013_bib14","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1084\/jem.20120950","article-title":"In\u00a0vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation","volume":"210","author":"Pichiorri","year":"2013","journal-title":"J.\u00a0Exp. Med."},{"issue":"8","key":"10.1016\/j.biomaterials.2018.03.013_bib15","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1021\/cr300362f","article-title":"MicroRNA: function, detection, and bioanalysis","volume":"113","author":"Dong","year":"2013","journal-title":"Chem. Rev."},{"issue":"11","key":"10.1016\/j.biomaterials.2018.03.013_bib16","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrd3864","article-title":"MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles, Nature reviews","volume":"11","author":"van Rooij","year":"2012","journal-title":"Drug Discover."},{"issue":"4","key":"10.1016\/j.biomaterials.2018.03.013_bib17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ccr.2010.03.008","article-title":"Sp1\/NFkappaB\/HDAC\/miR-29b regulatory network in KIT-driven myeloid leukemia","volume":"17","author":"Liu","year":"2010","journal-title":"Canc. Cell"},{"issue":"9","key":"10.1016\/j.biomaterials.2018.03.013_bib18","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1158\/1078-0432.CCR-12-3191","article-title":"Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia","volume":"19","author":"Huang","year":"2013","journal-title":"Clin. Canc. Res. Off. J. Am. Ass. Canc. Res."},{"issue":"10","key":"10.1016\/j.biomaterials.2018.03.013_bib19","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ncb2105","article-title":"A\u00a0Pumilio-induced RNA structure switch in p27-3' UTR controls miR-221 and miR-222 accessibility","volume":"12","author":"Kedde","year":"2010","journal-title":"Nat. Cell Biol."},{"issue":"15","key":"10.1016\/j.biomaterials.2018.03.013_bib20","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1038\/sj.emboj.7601790","article-title":"Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation","volume":"26","author":"le Sage","year":"2007","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.biomaterials.2018.03.013_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccr.2009.10.014","article-title":"miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation","volume":"16","author":"Garofalo M1","year":"2009","journal-title":"Canc. Cell"},{"issue":"5","key":"10.1016\/j.biomaterials.2018.03.013_bib22","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1158\/1078-0432.CCR-15-0489","article-title":"A\u00a013 mer LNA-i-mir-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells","volume":"22","author":"Gulla","year":"2016","journal-title":"Clin. Canc. Res. Off. J. Am. Ass. Canc. Res."},{"issue":"1","key":"10.1016\/j.biomaterials.2018.03.013_bib23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1073\/pnas.0907904107","article-title":"miR-221 overexpression contributes to liver tumorigenesis","volume":"107","author":"Pineau","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.biomaterials.2018.03.013_bib24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.drudis.2016.10.014","article-title":"miRNA nanotherapeutics for cancer","volume":"22","author":"Ganju","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.biomaterials.2018.03.013_bib25","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1172\/JCI84424","article-title":"Targeting noncoding RNAs in disease","volume":"127","author":"Adams","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"issue":"9","key":"10.1016\/j.biomaterials.2018.03.013_bib26","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1021\/acs.chemrev.5b00589","article-title":"Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies","volume":"116","author":"Ulbrich","year":"2016","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.biomaterials.2018.03.013_bib27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Canc."},{"issue":"3","key":"10.1016\/j.biomaterials.2018.03.013_bib28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.7150\/thno.18069","article-title":"Leukocyte-mediated delivery of nanotherapeutics in inflammatory and tumor sites","volume":"7","author":"Dong","year":"2017","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.biomaterials.2018.03.013_bib29","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.ymthe.2017.03.001","article-title":"Current progress in non-viral RNAi-based delivery strategies to lymphocytes","volume":"25","author":"Mizrahy","year":"2017","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.biomaterials.2018.03.013_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in\u00a0vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"19","key":"10.1016\/j.biomaterials.2018.03.013_bib31","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1002\/anie.200904359","article-title":"Gold nanoparticles for biology and medicine","volume":"49","author":"Giljohann","year":"2010","journal-title":"Angew. Chem."},{"issue":"5776","key":"10.1016\/j.biomaterials.2018.03.013_bib32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1126\/science.1125559","article-title":"Oligonucleotide-modified gold nanoparticles for intracellular gene regulation","volume":"312","author":"Rosi","year":"2006","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.biomaterials.2018.03.013_bib33","doi-asserted-by":"crossref","first-page":"10575","DOI":"10.1021\/acs.chemrev.5b00100","article-title":"Gold nanoparticles for in\u00a0vitro diagnostics","volume":"115","author":"Zhou","year":"2015","journal-title":"Chem. Rev."},{"issue":"7667","key":"10.1016\/j.biomaterials.2018.03.013_bib34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nature23306","article-title":"Integrative clinical genomics of metastatic cancer","volume":"548","author":"Robinson","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.biomaterials.2018.03.013_bib35","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Canc."},{"issue":"1","key":"10.1016\/j.biomaterials.2018.03.013_bib36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrg2918","article-title":"Network medicine: a network-based approach to human disease","volume":"12","author":"Barabasi","year":"2011","journal-title":"Nat. Rev. Genet."},{"issue":"8","key":"10.1016\/j.biomaterials.2018.03.013_bib37","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc.2016.56","article-title":"Biomarker development in the precision medicine era: lung cancer as a case study","volume":"16","author":"Vargas","year":"2016","journal-title":"Nat. Rev. Canc."},{"issue":"12","key":"10.1016\/j.biomaterials.2018.03.013_bib38","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1021\/ja4011145","article-title":"A\u00a0new nanotechnology technique for determining drug efficacy using targeted plasmonically enhanced single cell imaging spectroscopy","volume":"135","author":"Austin","year":"2013","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.biomaterials.2018.03.013_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2017.305","article-title":"A\u00a0regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness","author":"Yan","year":"2017","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.biomaterials.2018.03.013_bib40","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/leu.2015.56","article-title":"AML1\/ETO cooperates with HIF1 alpha to promote leukemogenesis through DNMT3 alpha transactivation","volume":"29","author":"Gao","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.biomaterials.2018.03.013_bib41","article-title":"A\u00a0vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target","author":"Yan","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.biomaterials.2018.03.013_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111777","article-title":"Regulation of RAB5C is important for the growth inhibitory effects of MiR-509 in human Precursor-B acute lymphoblastic leukemia","volume":"9","author":"Tan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biomaterials.2018.03.013_bib43","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-364","article-title":"Overexpression of primary microRNA 221\/222 in acute myeloid leukemia","volume":"13","author":"Rommer","year":"2013","journal-title":"BMC Canc."},{"issue":"2","key":"10.1016\/j.biomaterials.2018.03.013_bib44","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/leu.2015.253","article-title":"Prognostic significance of NPM1 mutation-modulated microRNA - mRNA regulation in acute myeloid leukemia","volume":"30","author":"Chiu","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.biomaterials.2018.03.013_bib45","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2014.03.006","article-title":"MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer","volume":"25","author":"Valeri","year":"2014","journal-title":"Canc. Cell"},{"key":"10.1016\/j.biomaterials.2018.03.013_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13884","article-title":"MicroRNA-182 targets SMAD7 to potentiate TGF beta-induced epithelial-mesenchymal transition and metastasis of cancer cells","volume":"7","author":"Yu","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biomaterials.2018.03.013_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbrc.2015.11.009","article-title":"miR-221 activates the NF-kappa B pathway by targeting A20","volume":"472","author":"Zhao","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.biomaterials.2018.03.013_bib48","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3109\/1061186X.2016.1172587","article-title":"Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles","volume":"24","author":"Ramishetti","year":"2016","journal-title":"J.\u00a0Drug Target."},{"issue":"10","key":"10.1016\/j.biomaterials.2018.03.013_bib49","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/ar2000138","article-title":"In\u00a0vivo targeted delivery of nanoparticles for theranosis","volume":"44","author":"Koo","year":"2011","journal-title":"Acc. Chem. Res."},{"issue":"27","key":"10.1016\/j.biomaterials.2018.03.013_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201701021","article-title":"Photosensitization priming of tumor microenvironments improves delivery of nanotherapeutics via neutrophil infiltration","volume":"29","author":"Chu","year":"2017","journal-title":"Adv Mater"},{"issue":"4","key":"10.1016\/j.biomaterials.2018.03.013_bib51","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1039\/C6SC04293G","article-title":"Nuclear-targeted siRNA delivery for long-term gene silencing","volume":"8","author":"Li","year":"2017","journal-title":"Chem. Sci."},{"issue":"5","key":"10.1016\/j.biomaterials.2018.03.013_bib52","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1021\/acs.analchem.6b03971","article-title":"Tracing the therapeutic process of targeted aptamer\/drug conjugate on cancer cells by surface-enhanced Raman scattering spectroscopy","volume":"89","author":"Deng","year":"2017","journal-title":"Anal. Chem."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961218301819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961218301819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:32:46Z","timestamp":1758904366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961218301819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":52,"alternative-id":["S0142961218301819"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2018.03.013","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2018.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}